Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice

• Published in: International journal of molecular sciences Vol. 21; no. 20; p. 7621
• Main Authors: Wang, Hui-Ching, Yeh, Tsung-Jang, Chan, Leong-Perng, Hsu, Chin-Mu, Cho, Shih-Feng
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 15.10.2020; MDPI
• Subjects: Animals; Biomarkers; Biomarkers, Tumor - genetics; Biomarkers, Tumor - immunology; Biomarkers, Tumor - metabolism; Cancer therapies; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - genetics; Carcinoma, Squamous Cell - immunology; Chemotherapy; Clinical medicine; Clinical trials; Epidermal growth factor; Gene expression; Head & neck cancer; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - genetics; Head and Neck Neoplasms - immunology; Human papillomavirus; Humans; Immune checkpoint inhibitors; Immune Checkpoint Inhibitors - therapeutic use; Immunotherapy; Ligands; Medical prognosis; Metastasis; Mutation Accumulation; Pharmacodynamics; Practice Guidelines as Topic; Regulatory approval; Response rates; Review; T-Lymphocytes - immunology; immune checkpoint inhibitor; head and neck cancer; biomarker; immunotherapy

Recurrent locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) is associated with dismal prognosis because of its highly invasive behavior and resistance to conventional intensive chemotherapy. The combination of targeted therapy and conventional chemotherapy has significantl...